Tesofensine for Weight Loss: Clinical Data

Key takeaways

• Tesofensine 0.5 mg produced 11.2% total body weight loss over 24 weeks in a Phase 2 trial of 203 obese adults [1]
• That’s 9.2 percentage points more than diet and placebo alone
• Weight loss was dose-dependent: 0.25 mg (6.5%), 0.5 mg (11.2%), 1.0 mg (12.6%) [1]
• The drug works through appetite suppression and increased energy expenditure, not through gut hormones
• Tesofensine is an oral tablet taken once daily
• It is not FDA-approved and not available for prescription

The Phase 2 trial data in detail

The primary weight loss data for tesofensine comes from a Phase 2, randomized, double-blind, placebo-controlled trial published in The Lancet in 2008 by Astrup and colleagues [1]. This remains the largest and most rigorous obesity trial for the drug.

Study design

The trial enrolled 203 obese adults (BMI 30-40 kg/m²) at five Danish obesity management centers. After a 2-week run-in period, participants were randomized to one of four groups:

• Tesofensine 0.25 mg once daily (n=52)
• Tesofensine 0.5 mg once daily (n=50)
• Tesofensine 1.0 mg once daily (n=49)
• Placebo (n=52)

All participants followed an energy-restricted diet. The treatment period lasted 24 weeks. The primary outcome was percentage change in body weight [1].

Weight loss results

The numbers tell a clear story:

Group	Total weight loss	Weight loss vs. placebo	P-value
Placebo + diet	2.0%	—	—
Tesofensine 0.25 mg	6.5%	4.5%	<0.0001
Tesofensine 0.5 mg	11.2%	9.2%	<0.0001
Tesofensine 1.0 mg	12.6%	10.6%	<0.0001

The response was clearly dose-dependent. Each step up in dose produced additional weight loss, though the jump from 0.5 mg to 1.0 mg was relatively small (1.4 percentage points) compared to the jump from 0.25 mg to 0.5 mg (4.7 percentage points) [1].

Body composition changes

This is where tesofensine gets interesting. The trial measured body composition via DEXA scans, and the weight loss was predominantly fat mass. At the 0.5 mg dose, the ratio of fat loss to lean mass loss was favorable compared to what’s typically seen with caloric restriction alone [1].

This matters because one of the criticisms of some weight loss medications is that they cause significant muscle loss alongside fat loss. The tesofensine data suggests the muscle-sparing effect may be better than diet alone, though the study wasn’t specifically powered to detect this.

Completion rate and adherence

Of the 203 randomized participants, 161 (79%) completed the full 24 weeks. Dropout rates were similar across groups. This is a respectable completion rate for a weight loss trial, where 30-40% dropout is common [1].

How tesofensine compares to other weight loss drugs

Putting these numbers in context requires comparing them to other drugs tested in similar timeframes.

Semaglutide (Wegovy)

In the STEP 1 trial, semaglutide 2.4 mg produced 14.9% body weight loss over 68 weeks (vs. 2.4% for placebo). Over 24 weeks, the weight loss with semaglutide was approximately 10-11%. The 24-week comparison is roughly similar to tesofensine 0.5 mg, though the trial designs, populations, and dietary interventions differed [1].

The key difference: semaglutide has completed multiple Phase 3 trials with thousands of patients. Tesofensine has Phase 2 data from 203 patients. The depth of evidence isn’t comparable.

Tirzepatide (Zepbound)

Tirzepatide produced up to 22.5% weight loss at the highest dose (15 mg) over 72 weeks in the SURMOUNT-1 trial. Even at 24 weeks, tirzepatide’s weight loss curves were steep. This puts tirzepatide ahead of tesofensine in absolute weight loss, though tesofensine’s oral tablet format and different mechanism remain potential advantages for certain patients [1].

For a detailed comparison of these GLP-1 drugs, see our semaglutide vs tirzepatide guide.

CagriSema

CagriSema (cagrilintide + semaglutide) produced 20.4% weight loss over 68 weeks in the REDEFINE 1 trial [7]. This combination represents the current frontier of pharmacological weight loss. Tesofensine’s numbers, while strong for a single-agent oral drug, don’t match the newer combination injectables.

Phentermine

Phentermine typically produces 5-8% weight loss over 12-24 weeks. Tesofensine 0.5 mg roughly doubled this, which led the Lancet authors to conclude that tesofensine “might have the potential to produce a weight loss twice that of currently approved drugs” [1].

Naltrexone-bupropion (Contrave)

Contrave produced approximately 5-6% weight loss in its key clinical trials. Tesofensine 0.5 mg produced roughly twice as much weight loss, likely because its triple-reuptake mechanism covers serotonin in addition to the dopamine and noradrenaline pathways that bupropion targets [1].

The mechanism behind the weight loss

Tesofensine produces weight loss through two simultaneous effects.

Reduced calorie intake. An analysis of the Phase 2 appetite data showed that tesofensine increased composite satiety scores in a dose-dependent manner at week 12 (r = 0.36, P < 0.0001 correlation with weight loss). Participants reported feeling fuller sooner and less hungry between meals [2].

Increased energy expenditure. The noradrenaline reuptake inhibition boosts metabolic rate. A 2012 study in diet-induced obese rats showed tesofensine decreased food intake and reduced striatal dopamine D2/D3 receptor availability, confirming both the appetite-suppressive and metabolic effects seen in humans [3].

This dual mechanism is different from GLP-1 drugs, which primarily reduce calorie intake by slowing gastric emptying and increasing satiety signaling. Tesofensine doesn’t affect gut motility at all. For more on how various peptides affect metabolism, see our dedicated guide.

The oral tablet advantage

One practical advantage that gets overlooked in clinical discussions: tesofensine is taken as a once-daily oral tablet.

Most of the newer weight loss medications require weekly subcutaneous injections. For many patients, that’s a non-issue. But a significant portion of people avoid injectable medications due to needle phobia, inconvenience, or cold storage requirements.

An oral tablet that produces 11% weight loss in 24 weeks would be a meaningful addition to the available options, particularly for patients who’ve avoided or discontinued injectable therapies. The few oral weight loss drugs currently available (phentermine, Contrave, orlistat) produce substantially less weight loss [1].

Weight loss in hypothalamic obesity

A 2022 randomized trial tested Tesomet (tesofensine 0.5 mg + metoprolol 50 mg) in 21 adults with hypothalamic obesity. This condition typically results from brain surgery, tumor treatment, or traumatic injury to the hypothalamus, and it’s considered one of the hardest forms of obesity to treat [4].

Results over 24 weeks:

• Tesomet group: 6.3% additional weight loss vs. placebo (P = 0.017)
• 8 of 13 Tesomet patients (62%) achieved at least 5% weight loss
• 1 of 8 placebo patients (12.5%) achieved at least 5% weight loss

While the absolute weight loss was lower than in the general obesity trial, achieving any weight loss in hypothalamic obesity is noteworthy. Conventional lifestyle interventions and most weight loss medications are typically ineffective in this population [4].

Timeline: what to expect

Based on the Phase 2 trial data and the appetite analysis [2], here’s a rough timeline:

Weeks 1-4: Appetite suppression begins. Participants notice feeling less hungry and more satisfied after meals. Most of the early side effects (dry mouth, insomnia) appear during this period.

Weeks 4-12: The peak appetite-suppressing effect occurs around week 12. Weight loss is steady and accelerating. Most participants are losing 1-2% of body weight per month.

Weeks 12-24: Weight loss continues but the rate may slow slightly. The appetite suppression effect appears to partially diminish between weeks 12 and 24, though weight loss continues due to the metabolic effects [2].

After stopping: Satiety scores return to baseline after drug withdrawal, even in the reduced-weight state [2]. This suggests weight regain is likely without continued treatment, similar to what’s observed with other weight loss medications.

The evidence gaps

A few things the current data doesn’t tell us:

Weight loss beyond 24 weeks. The Phase 2 trial lasted 24 weeks. We don’t know if weight loss plateaus, continues, or partially reverses with longer treatment.

Real-world effectiveness. Clinical trial participants are more adherent than average patients. Real-world weight loss is typically 30-50% less than trial results for most drugs.

Combination potential. No studies have tested tesofensine combined with GLP-1 drugs or other weight loss agents. The different mechanisms suggest combination therapy could be additive, but this is speculation.

Who responds best. The Phase 2 trial didn’t identify clear predictors of response. We don’t know if certain patient characteristics (age, sex, baseline BMI, eating patterns) predict better outcomes.

Frequently asked questions

How fast does tesofensine work for weight loss?▼

Based on the Phase 2 trial, weight loss is apparent within the first month. The appetite-suppressing effect peaks around 12 weeks. Over 24 weeks, participants on the 0.5 mg dose lost an average of 11.2% of their body weight [1].

Is tesofensine better than Ozempic for weight loss?▼

The comparison is complicated. In similar timeframes (24 weeks), the weight loss numbers are roughly comparable. But semaglutide has Phase 3 data showing continued weight loss out to 68 weeks (14.9% total), while tesofensine’s longest trial data is 24 weeks. Semaglutide also has years of real-world safety and efficacy data that tesofensine lacks [1].

Can you get tesofensine as a prescription?▼

No. Tesofensine is not FDA-approved for any indication. It is not available through pharmacies, compounding pharmacies, or telehealth services. Any products sold as “tesofensine” online are unregulated research chemicals.

Does the weight stay off after stopping tesofensine?▼

The appetite data suggests it probably doesn’t. When participants stopped tesofensine in the Phase 2 study, their satiety scores returned to baseline values despite being at a lower weight [2]. This pattern is consistent with other weight loss medications, where weight regain after discontinuation is the norm.

What dose of tesofensine works best for weight loss?▼

The 0.5 mg dose provides the best balance of efficacy and tolerability. It produced 11.2% weight loss (vs. 12.6% at 1.0 mg), but with fewer side effects, particularly regarding heart rate elevation [1].

Is tesofensine available through compounding pharmacies?▼

No. Tesofensine is an investigational drug that has not been approved by the FDA. Compounding pharmacies can only compound drugs that contain FDA-approved active ingredients. For information on approved weight loss treatments, see our guide on how to get peptides prescribed.

How does tesofensine produce weight loss differently than GLP-1 drugs?▼

GLP-1 drugs mimic gut hormones to slow stomach emptying and signal fullness. Tesofensine blocks the reuptake of serotonin, dopamine, and noradrenaline in the brain, which reduces appetite through reward and satiety circuits while also increasing metabolic rate. These are completely separate pathways [1, 5].

References

1. Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. https://pubmed.ncbi.nlm.nih.gov/18950853/

2. Gilbert JA, Gasteyger C, Raben A, et al. The effect of tesofensine on appetite sensations. Obesity. 2012;20(3):553-561. https://pubmed.ncbi.nlm.nih.gov/21720440/

3. Appel NM, et al. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. Eur Neuropsychopharmacol. 2012;22(4):290-299. https://pubmed.ncbi.nlm.nih.gov/21889317/

4. Huynh K, Klose M, Krogsgaard K, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022;186(6):687-700. https://pubmed.ncbi.nlm.nih.gov/35294397/

5. Heal DJ, Gosden J, Smith SL. Centrally acting agents for obesity: past, present, and future. Drugs. 2018;78(11):1113-1132. https://pubmed.ncbi.nlm.nih.gov/30014268/

6. Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep. 2018;7(2):147-161. https://pubmed.ncbi.nlm.nih.gov/29504049/

7. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393(7):635-647. https://pubmed.ncbi.nlm.nih.gov/40544433/

8. Bhatt DK, et al. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS ONE. 2024;19(4):e0301826. https://pubmed.ncbi.nlm.nih.gov/38656972/